| Autor: |
Rothen DA; Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland.; Department of Immunology RIA, University Hospital Bern, 3010 Bern, Switzerland.; Graduate School of Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland., Dutta SK; Artemis Bio-Services, 2629 JD Delft, The Netherlands., Krenger PS; Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland.; Department of Immunology RIA, University Hospital Bern, 3010 Bern, Switzerland.; Graduate School of Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland., Pardini A; Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland.; Department of Immunology RIA, University Hospital Bern, 3010 Bern, Switzerland.; Graduate School of Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland., Vogt AS; Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland.; Department of Immunology RIA, University Hospital Bern, 3010 Bern, Switzerland.; Graduate School of Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland., Josi R; Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland.; Department of Immunology RIA, University Hospital Bern, 3010 Bern, Switzerland.; Graduate School of Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland., Lieknina I; Latvian Biomedical Research & Study Centre, Ratsupites iela 1, 1067 Riga, Latvia., Osterhaus ADME; Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, 30559 Hannover, Germany., Mohsen MO; Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland.; Department of Immunology RIA, University Hospital Bern, 3010 Bern, Switzerland., Vogel M; Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland.; Department of Immunology RIA, University Hospital Bern, 3010 Bern, Switzerland., Martina B; Artemis Bio-Services, 2629 JD Delft, The Netherlands., Tars K; Latvian Biomedical Research & Study Centre, Ratsupites iela 1, 1067 Riga, Latvia., Bachmann MF; Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland.; Department of Immunology RIA, University Hospital Bern, 3010 Bern, Switzerland.; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK. |
| Abstrakt: |
Declared as a Public Health Emergency in 2016 by the World Health Organization (WHO), the Zika virus (ZIKV) continues to cause outbreaks that are linked to increased neurological complications. Transmitted mainly by Aedes mosquitoes, the virus is spread mostly amongst several tropical regions with the potential of territorial expansion due to environmental and ecological changes. The ZIKV envelope protein's domain III, crucial for vaccine development due to its role in receptor binding and neutralizing antibody targeting, was integrated into sterically optimized AP205 VLPs to create an EDIII-based VLP vaccine. To increase the potential size of domains that can be accommodated by AP205, two AP205 monomers were fused into a dimer, resulting in 90 rather than 180 N-/C- termini amenable for fusion. EDIII displayed on AP205 VLPs has several immunological advantages, like a repetitive surface, a size of 20-200 nm (another PASP), and packaged bacterial RNA as adjuvants (a natural toll-like receptor 7/8 ligand). In this study, we evaluated a novel vaccine candidate for safety and immunogenicity in mice, demonstrating its ability to induce high-affinity, ZIKV-neutralizing antibodies without significant disease-enhancing properties. Due to the close genetical and structural characteristics, the same mosquito vectors, and the same ecological niche of the dengue virus and Zika virus, a vaccine covering all four Dengue viruses (DENV) serotypes as well as ZIKV would be of significant interest. We co-formulated the ZIKV vaccine with recently developed DENV vaccines based on the same AP205 VLP platform and tested the vaccine mix in a murine model. This combinatory vaccine effectively induced a strong humoral immune response and neutralized all five targeted viruses after two doses, with no significant antibody-dependent enhancement (ADE) observed. Overall, these findings highlight the potential of the AP205 VLP-based combinatory vaccine as a promising approach for providing broad protection against DENV and ZIKV infections. Further investigations and preclinical studies are required to advance this vaccine candidate toward potential use in human populations. |
